Samuel Drennan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samuel Drennan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Eli Wagnell
Oregon Health and Science University
1 shared publication - Elise C. Manalo
Oregon Health and Science University
1 shared publication - Jared Michael Fischer
CEDAR Knight Cancer Institute School of Medicine Oregon Health and Science University Portland Oregon 97201 USA
1 shared publication - Justin Merritt
Division of Biomaterial and Biomedical Sciences, School of Dentistry, Oregon Health & Science University (OHSU), Portland, OR, USA
1 shared publication - Michael Brasino
Cancer Early Detection Advanced Research (CEDAR) Center, Knight Cancer Institute, School of Medicine, Oregon Health and Science University, Portland, Oregon, USA
1 shared publication
Latest Publications
- Open Access
Engineered Lactiplantibacillus plantarum as a Biosensor Probe for the Lungs
Lungs are a frequent site for disease but are difficult to image and probe, potentially exacerbating lung disease, delaying diagnoses and impacting survival. Here, we demonstrate a low cost, minimally invasive method to probe the lungs for disease, using genetically engineered Lactiplantibacillus plantarum strain WCFS1. Genetically modified WCFS1 was delivered specifically to the lungs of mice, where it was shown to remain transcriptionally active for several hours and then be cleared without further colonization. WCFS1 was further modified to secrete nanoluciferase as a synthetic biomarker, which traveled from the bacteria in the lung to the urine where it was easily detected. The administered bacteria also secreted nano-luciferase upon detecting a specific peptide secreted by a mouse lung cancer cell line in vitro or in vivo from syngeneic tumors.
Open AccessEngineered Lactiplantibacillus plantarum as a Biosensor Probe for the Lungs
Lungs are a frequent site for disease but are difficult to image and probe, potentially exacerbating lung disease, delaying diagnoses and impacting survival. Here, we demonstrate a low cost, minimally invasive method to probe the lungs for disease, using genetically engineered Lactiplantibacillus plantarum strain WCFS1. Genetically modified WCFS1 was delivered specifically to the lungs of mice, where it was shown to remain transcriptionally active for several hours and then be cleared without further colonization. WCFS1 was further modified to secrete nanoluciferase as a synthetic biomarker, which traveled from the bacteria in the lung to the urine where it was easily detected. The administered bacteria also secreted nano-luciferase upon detecting a specific peptide secreted by a mouse lung cancer cell line in vitro or in vivo from syngeneic tumors.